KR100814218B1 - 습식 과립화에 의해서 제조된 아토르바스타틴의 안정한조성물 - Google Patents

습식 과립화에 의해서 제조된 아토르바스타틴의 안정한조성물 Download PDF

Info

Publication number
KR100814218B1
KR100814218B1 KR1020057023669A KR20057023669A KR100814218B1 KR 100814218 B1 KR100814218 B1 KR 100814218B1 KR 1020057023669 A KR1020057023669 A KR 1020057023669A KR 20057023669 A KR20057023669 A KR 20057023669A KR 100814218 B1 KR100814218 B1 KR 100814218B1
Authority
KR
South Korea
Prior art keywords
atorvastatin
granules
wet
composition
optionally
Prior art date
Application number
KR1020057023669A
Other languages
English (en)
Korean (ko)
Other versions
KR20060020666A (ko
Inventor
케네쓰 크레이그 워터만
마이클 브루스 퍼지온
바바라 앨리스 존슨
Original Assignee
워너-램버트 캄파니 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 워너-램버트 캄파니 엘엘씨 filed Critical 워너-램버트 캄파니 엘엘씨
Publication of KR20060020666A publication Critical patent/KR20060020666A/ko
Application granted granted Critical
Publication of KR100814218B1 publication Critical patent/KR100814218B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
KR1020057023669A 2003-06-12 2004-06-01 습식 과립화에 의해서 제조된 아토르바스타틴의 안정한조성물 KR100814218B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47811903P 2003-06-12 2003-06-12
US60/478,119 2003-06-12

Publications (2)

Publication Number Publication Date
KR20060020666A KR20060020666A (ko) 2006-03-06
KR100814218B1 true KR100814218B1 (ko) 2008-03-17

Family

ID=33551806

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057023669A KR100814218B1 (ko) 2003-06-12 2004-06-01 습식 과립화에 의해서 제조된 아토르바스타틴의 안정한조성물

Country Status (15)

Country Link
EP (1) EP1635814A1 (fr)
JP (1) JP2006527260A (fr)
KR (1) KR100814218B1 (fr)
CN (1) CN100434069C (fr)
AR (1) AR044774A1 (fr)
AU (1) AU2004246868B2 (fr)
BR (1) BRPI0411344A (fr)
CA (1) CA2465565A1 (fr)
CO (1) CO5650230A2 (fr)
MX (1) MXPA05013281A (fr)
NO (1) NO20060022L (fr)
NZ (1) NZ543337A (fr)
RU (1) RU2332211C2 (fr)
TW (1) TW200503690A (fr)
WO (1) WO2004110431A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CA2691956A1 (fr) * 2007-06-25 2008-12-31 Pharmathen S.A. Formulation pharmaceutique amelioree contenant un inhibiteur de la hmg-coa reductase et son procede de preparation
CA2716671A1 (fr) * 2008-02-27 2009-09-03 Thommen Medical Ag Implant et procede de fabrication
JP5714492B2 (ja) * 2008-09-17 2015-05-07 マイラン インコーポレイテッド 粒状体、それらの調製方法、およびそれらを含む医薬品
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN104069078B (zh) * 2014-05-22 2019-06-11 西藏九瑞健康股份有限公司 阿托伐他汀钙药物组合物及其制备方法
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
KR101658350B1 (ko) * 2015-02-06 2016-09-30 경성대학교 산학협력단 고지혈증 치료에 유용한 약학 조성물
WO2016145132A1 (fr) * 2015-03-12 2016-09-15 Fmc Corporation Dispersions solides
CN109152787A (zh) 2016-03-31 2019-01-04 英特塞普特医药品公司 具有优越的溶出性的口服制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (fr) * 1993-01-19 1994-08-04 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
JP3014040B2 (ja) * 1996-10-30 2000-02-28 信久 川野 食物繊維パン及びその製造法
ATE524163T1 (de) * 2000-04-10 2011-09-15 Teva Pharma Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
EP1226818A1 (fr) * 2001-01-26 2002-07-31 Pfizer Products Inc. Formulation pharmaceutique présentant des propriétés de cohesion et de compressibilité améliorées
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06242003A (ja) * 1993-02-12 1994-09-02 Nkk Corp 鉄鋼中のアルミナの粒度測定方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
미국공개특허 제6,242,003호

Also Published As

Publication number Publication date
KR20060020666A (ko) 2006-03-06
TW200503690A (en) 2005-02-01
AR044774A1 (es) 2005-10-05
RU2332211C2 (ru) 2008-08-27
NO20060022L (no) 2006-01-03
CN100434069C (zh) 2008-11-19
CO5650230A2 (es) 2006-06-30
AU2004246868A1 (en) 2004-12-23
WO2004110431A1 (fr) 2004-12-23
NZ543337A (en) 2008-03-28
CN1805741A (zh) 2006-07-19
CA2465565A1 (fr) 2004-12-12
BRPI0411344A (pt) 2006-07-11
MXPA05013281A (es) 2006-03-09
JP2006527260A (ja) 2006-11-30
RU2005136745A (ru) 2006-07-27
AU2004246868B2 (en) 2008-01-17
EP1635814A1 (fr) 2006-03-22

Similar Documents

Publication Publication Date Title
US7790197B2 (en) Pharmaceutical compositions of atorvastatin
US20090226510A1 (en) Pharmaceutical compositions of atorvastatin
KR101380088B1 (ko) 약학 조성물
CA2474674C (fr) Preparation solide contenant une forme monocristalline
ES2325764T3 (es) Preparaciones orales con buenas caracteristicas de desintegracion.
US20090196932A1 (en) Pharmaceutical compositions of atorvastatin
JP2004533999A (ja) 医薬形態のアトルバスタチンカルシウム、その構成物、及びアトルバスタチンカルシウムを含む医薬製剤
KR100814218B1 (ko) 습식 과립화에 의해서 제조된 아토르바스타틴의 안정한조성물
KR100760112B1 (ko) 아토르바스타틴의 제약 조성물
WO2010098482A1 (fr) Préparation de capsules stable et son procédé de fabrication
WO2005123138A1 (fr) Compositions de pastilles pharmaceutiques a liberation controlee
AU2008200759A1 (en) Stable compositions of atorvastatin prepared with wet granulation
WO2023217694A1 (fr) Composition pharmaceutique d'acide bempédoïque

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Publication of correction
LAPS Lapse due to unpaid annual fee